Analys

PROLIGHT: Positive results from the pre-clinical validation study de-risk the full clinical validation

Analys, Research

Following the many recent grants, notices of allowance and intention to grant patents in Europe and the US, and the arrival of the first of...

Read More

NANEXA: Targeting treatment of first patient in phase Ib/II with NEX-22 before year-end

Analys, Research

Nanexa’s Q4 report did not reveal much new, although the conference call provided welcome clarity on the rationale behind the extension...

Read More

CRUNCHFISH: Still in the running for a one billion-user Digital Cash market

Analys, Research

Johan Widmark | 2025-02-14 08:00  READ FULL REPORT IN PDF HERE Small signs pointing towards a system-wide deal in India At the...

Read More

NANEXA: Financing secured into 2026 to drive NEX-22 development

Analys, Research

Johan Widmark | 2025-01-27 08:00  READ FULL REPORT HERE IN PDF With the directed issue of units amounting to SEK 35m, supplemented by SEK...

Read More

GRANGEX: PEA confirmns robust economics for Sydvaranger – mapping the road to financial close in H2’25

Analys, Research

With the release of a Preliminary Economic Assessment (PEA) for the restart of the Sydvaranger mine, GRANGEX now has more clarity on the...

Read More

PROLIGHT: SpinChip deal highlights the strategic importance and valuation potential of Prolight’s solution

Analys, Research

The recent acquisition of Norwegian point-of-care diagnostics platform SpinChip by bioMérieux for EUR 138 million underscores the growing...

Read More

PROLIGHT: Commercial prototype marks an important milestone towards upcoming studies

Analys, Research

The arrival of the first commercial prototype instruments for Prolight’s Psyros Point of Care (POC) system marks an important development...

Read More

PROLIGHT: Advancing with strengthened financials towards clinical performance study in 2025

Analys, Research

Prolight continues to make progress with its proprietary Psyros platform, with a pre-validation study, including fresh blood samples from...

Read More

NANEXA: Progress for rival at Novo illustrates the significant value potential in Nanexa

Analys, Research

NEX-22 is progressing as expected, with the last patient in Phase I treated, results anticipated later in November, and Phase IIb scheduled...

Read More

CRUNCHFISH: Q3 report webinar

Analys, Research

On Friday Nov 1st, 2024 Crunchfish hosted a webinar in connection with the Q3’24 report, where CEO Joachim Samulesson was interviewed...

Read More

For new research on growth stocks, sign up to our newsletter